Roberta Diaz Brinton

Roberta Diaz Brinton

Director/Board Member at Alzheimers Drug Discovery Foundation

26 connections
Health Technology

Profile

Roberta Diaz Brinton currently works at Alzheimers Drug Discovery Foundation, as Member-Governors Board.

Roberta Diaz Brinton active positions

CompaniesPositionStart
Alzheimers Drug Discovery Foundation
Logo Alzheimers Drug Discovery Foundation

Alzheimers Drug Discovery Foundation

BiotechnologyHealth Technology

The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr.

 Director/Board Member -
All active positions of Roberta Diaz Brinton

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Roberta Diaz Brinton's experience

Connections

26

1st degree connections

1

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies1
Alzheimers Drug Discovery Foundation
Logo Alzheimers Drug Discovery Foundation

Alzheimers Drug Discovery Foundation

BiotechnologyHealth Technology

The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr.

Health Technology

See company connections
  1. Stock Market
  2. Insiders
  3. Roberta Diaz Brinton